patient with cardiac arrest, as initial presentation of the underlying cardiac disease, who receives an implantable cardioverter-defibrillator, cost cannot be evaluated, unless the first line therapeutic option for these patients is not an implantable cardioverter-defibrillator. Another approach could be to randomize these patients to an implantable cardioverter-defibrillator or to other forms ...

OBJECTIVE To review the evidence base from randomised controlled trials of combined cardiac resynchronisation therapy and implantable cardioverter defibrillator therapy in left ventricular impairment and symptomatic heart failure. DESIGN Bayesian network meta-analysis. DATA SOURCES Medline, Embase, and Cochrane databases up to June 2006. REVIEW METHODS Two reviewers independently assessed...

AIMS Benefits and complications of postoperative implantable cardioverter-defibrillator tests are controversial matters. This study sought to assess the necessity of defibrillation function tests after implantation. METHODS AND RESULTS We retrospectively analysed 1007 implantable cardioverter-defibrillator tests in 587 systems and 556 patients. Nine hundred and thirty implantable cardioverter...

OBJECTIVE The Copenhagen Outpatient ProgrammE - implantable cardioverter defibrillator (COPE-ICD) trial included patients with implantable cardioverter defibrillators in a randomized controlled trial of rehabilitation. After 6-12 months significant differences were found in favour of the rehabilitation group for exercise capacity, general and mental health. The aim of this paper is to explore t...

antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the cardiac arrest study hamburg (CASH). Circulation 2000;102:748–754. 9. Daubert JP, Sesselberg HW, Huang DT. Implantable cardioverterdefibrillators for primary prevention: how do the data pertain to the aged? Am J Geriatr Cardiol 2006;15:88–92. 10. Wilkoff BL, Cook JR, Epstein AE, Greene ...

BACKGROUND Reticular telangiectatic erythema is a benign cutaneous reaction that may occur in patients who have received a subcutaneous implantable cardioverter-defibrillator. Reticular telangiectatic erythema is characterized by asymptomatic telangiectasias, blanchable erythematous patches, or both overlying and/or adjacent to the subcutaneous implantable cardioverter-defibrillator. PURPOSE ...

BACKGROUND Dysrhythmia is one of the most common causes of sudden cardiac death worldwide. An implantable cardioverter defibrillator is the most effective method of treatment for dysrhythmias causing cardiac arrest. However, living with an implantable cardioverter defibrillator is associated with challenges such as fear, anxiety, and depression. OBJECTIVES The purpose of this study was to ide...

In this report we briefly describe a patient with a dual chamber implantable cardioverter defibrillator in the context of severe ischemic cardiomyopathy who developed persistent atrial fibrillation. After appropriate anticoagulation and under mild sedation the patient was successfully cardioverted to sinus rhythm after a programmed ventricular synchronized defibrillation using his defibrillator...

BACKGROUND Studies of cardiac resynchronization therapy in addition to an implantable cardioverter defibrillator in patients with mild to moderate congestive heart failure had not been shown to reduce mortality until the recent RAFT trial (Resynchronization/Defibrillation for Ambulatory Heart Failure Trial). We performed a meta-analysis including the RAFT trial to determine the effect of cardia...